Opens in a new tab

GlaxoSmithKline Biologicals v C.P. Pharmaceuticals International C.V. (CFI, 10 August 2026)

Date10 August 2026
CourtCFI
DivisionThe Hague (NL) Local Division
Type of actionInfringement Action
Case number(s)UPC_CFI_621/2025
Registry referenceUPC_CFI_621/2025
PartiesGlaxoSmithKline Biologicals SA v. C.P. Pharmaceuticals International C.V., Pfizer Export B.V., Pfizer B.V., Pfizer Manufacturing Belgium N.V.,…

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 10 August 2026 (UPC_CFI_621/2025, UPC_CFI_1707/2025 and UPC_CFI_1708/2025), The Hague Local Division deals, in the dispute between GlaxoSmithKline Biologicals SA and companies of the Pfizer and BioNTech groups, with the consequences of EPO decisions on two divisional patents stemming from the same application. EP 4 066 856 having been finally revoked by the Technical Board of Appeal on 20 July 2026, the counterclaim directed at it is disposed of as devoid of purpose. For EP 4 226 941, revoked in opposition on 24 June 2026, the division postpones its decision on the stay request and cancels the oral hearing of 30 September 2026, pending the Board’s written reasons.

Question

Should the division rule at once on a stay request under Rule 295 where the Technical Board of Appeal has revoked a related divisional patent but has not yet issued its reasons?

Decision

As the parties agree that there is no need to adjudicate the counterclaim against EP 4 066 856, the division closes that file and orders GSK, as the unsuccessful party, to bear the costs, the amount to be determined later (paragraph 6), on this point the order refers to the costs of “Moderna”, which is not a party to these proceedings. The revocation of that patent has only partial implications for the infringement action, which also rests on EP 4 226 941 (paragraph 7). The likelihood that the latter’s claims will be held invalid is relevant to the stay, but can only be assessed in the light of the Board’s written reasons (paragraph 8). The parties may file submissions within four weeks of those reasons and reply within three weeks.

Key points for practice

Provisions applied

Rules of Procedure
Rules 9, 295 and 360
Case law cited
No UPC decision, the order refers to the decisions of the EPO Opposition Division of 24 June 2026 and of the Technical Board of Appeal of 20 July 2026.

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.

Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.

Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CFI_621/2025 official number

Follow this case

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Infringement Action
Outcome (Dhenne Avocats summary)
La demande reconventionnelle visant EP 4 066 856, définitivement révoqué par l’OEB, est déclarée sans objet, frais à la charge de GSK. La décision sur le sursis concernant EP 4 226 941 est reportée et l’audience du 30 septembre 2026 annulée.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

  • EP 4 066 856 mentioned in: summary of the decision, Dhenne Avocats analysis Follow this patent
  • EP 4 226 941 mentioned in: summary of the decision, Dhenne Avocats analysis Follow this patent
Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 4 066 856Patent at issue according to the summary or official headnote
Also mentioned in 3 other decision(s): GlaxoSmithKline Biologicals v Moderna Netherlands (CFI, 10 August 2026 · GlaxoSmithKline Biologicals v Moderna (CFI, 25 February 2026) · GlaxoSmithKline Biologicals v Moderna Netherlands (CFI, 28 November 20
not recordednot recordednot recordedEspacenet
links not checked
mentioned in: summary of the decision, Dhenne Avocats analysis
EP 4 226 941Patent at issue according to the summary or official headnote
Also mentioned in 3 other decision(s): GlaxoSmithKline Biologicals v Moderna Netherlands (CFI, 10 August 2026 · GlaxoSmithKline Biologicals v Moderna (CFI, 25 February 2026) · GlaxoSmithKline Biologicals v Moderna Netherlands (CFI, 28 November 20
not recordednot recordednot recordedEspacenet
links not checked
mentioned in: summary of the decision, Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.